StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Fabhalta (iptacopan by Quarter

Fabhalta (iptacopan — paroxysmal nocturnal hemoglobinuria PNH & IgAN/C3G kidney disease) ($M)

QuarterlyAnnual

Novartis Fabhalta (iptacopan: $237M in Q3 2026, up 59.1% from a year earlier. That is the highest of the 12 quarters on record here.

Latest, Q3 2026
237
Period ended Sep 30, 2026
Change on a year earlier
+59.1%
149 in Q3 2025
History
12 quarters
Since Q4 2023
Sources
8
Documents cited below

Where the Q3 2026 figure comes from

“|| Fabhalta 3 | 237 | 149 | 59 | 60”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFabhalta (iptacopan — paroxysmal nocturnal hemoglobinuria PNH & IgAN/C3G kidney disease) ($M)Year on yearSource
Q3 2026Sep 30, 2026237+59.1%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026225+87.5%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026169+108.6%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025155+171.9%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025149+238.6%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 2025120+445.5%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 202581+1,250.0%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 202457+5,600.0%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 202444–Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 202422–Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 20246–Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 20231–Novartis Form 6-K (0001370368-25-000007) ↗

Breakdown

What makes up fabhalta (iptacopan

Cite this data

StockData. (2026). Novartis Fabhalta (iptacopan ($M), quarterly Q4 2023–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-fabhalta

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.